Skip to content
Resources > Reports

Hedgeweek-AIMA Allocator Sentiment Report H1 2026

Allocators are no longer chasing the next star manager. In 2026, the focus has shifted to extracting value, managing risk, and building resilient portfolios in volatile markets.

Produced by Hedgeweek and AIMA, and sponsored by AlphaSense, this report draws on insights from 100+ global hedge fund allocators, revealing how allocation strategies, risk priorities, and research workflows are evolving in 2026.

The report also features expert commentary and a Q&A with Frank Nash, SVP at AlphaSense, examining how AI-driven research is accelerating analysis, sharpening conviction, and reshaping how allocators assess managers and risk.

Inside the report:

  • Why allocator confidence is rising — even as 59% plan to keep allocations unchanged
  • The shift from manager hunting to portfolio optimisation
  • Why diversification and uncorrelated returns now matter more than chasing returns

Download the full report for the data and allocator insights shaping hedge fund allocation decisions in 2026.

Explore more

APAC Macro Briefing 2026: Risk Meets Opportunity

In this report, we show how resources and workflows available in the AlphaSense platform can help contextualize the APAC macro environment, exploring the key implications for corporate leaders and investors across sectors.
Title slide for "APAC Macro Briefing 2026: Risk Meets Opportunity" with a map of the Asia-Pacific region.

Top AI Use Cases for Private Equity

In this report, discover how private equity teams are leveraging AI to accelerate conviction with speed. With purpose built, AI-driven solutions like AlphaSense, teams are gaining a competitive advantage with custom workflows and unmatched content sets for the most differentiated deal intelligence.
Top AI Use Cases For Private Equity by Barb Tague, Financial Research Leader. Illustration featuring isometric buildings and currency symbols.

AI in Drug Development 2026: From Experimentation to Execution

Learn how AI is reshaping drug development in real time, turning AI execution into a key competitive differentiator.
Presentation slide titled "AI in Drug Development 2026: From Experimentation to Execution" by Sara Mallatt and Sean Carmichael, with line art of laboratory equipment.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.